Ardena Invests US$20 million for State-of-the-Art Nanomedicine Facility in Netherlands
Introduction:
Ardena plans to invest US$20 million to open new expanded nanomedicine facility in Oss, Netherlands.
Features:
This cutting-edge 45,000-square-foot facility is designed specifically for nanomedicine manufacturing, featuring GMP-compliant Grade C and Grade D cleanrooms.
The facility also includes tailored production areas, dedicated laboratories for process development and analytical testing, and advanced warehousing capabilities.
The expanded infrastructure supports the manufacturing and GMP release of nanomedicines, including advanced nanoparticulate drug delivery systems, imaging agents, and tissue engineering products.
It is equipped to accommodate a broad spectrum of nanomedicines, such as lipid-based nanoparticles (LNPs, liposomes, and lipid micelles), polymeric nanoparticles (polymer micelles and dendrimer-based nanoparticles), and metal/metal oxide nanoparticles (gold, silica, and iron oxide).
The Oss facility features specialised automated manufacturing workflows and advanced analytical capabilities for characterising complex nanomedicine formulations. These advancements enable scalable operations while upholding the highest standards of quality and efficiency.
This integrated setup ensures seamless, end-to-end support for clinical supply, offering a significant advantage for injectable nanomedicine formulations.
Specifications:
| Name : | Ardena |
| Type : | New Construction |
| Year : | US$20 million |
